other material
confidence high
sentiment neutral
materiality 0.80
Sunshine Biopharma prices and closes $6.0M public offering, with up to $14.4M more if Series D warrants exercised
Sunshine Biopharma Inc.
- On October 8, 2026, Sunshine Biopharma entered a placement agent agreement with Aegis Capital Corp. for a best-efforts public offering of Common Units and Pre-Funded Units.
- The offering priced at $0.55 per Common Unit and $0.54999 per Pre-Funded Unit; gross proceeds were about $6.0 million before fees and expenses.
- The offering included 10,509,082 Common Units and 400,000 Pre-Funded Units, each with two Series D warrants exercisable at $0.66 and expiring five years after issuance.
- The closing occurred October 9, 2026; the Series D warrants could raise up to approximately $14.4 million if fully exercised for cash.
- Aegis Capital Corp. received a 7% placement agent fee and a 1% non-accountable expense allowance; Sichenzia Ross Ference Carmel LLP and Kaufman & Canoles, P.C. acted as counsel.